| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-11-29 | ORMD-0901 (oral exenatide) | type 2 diabetes | 1b | Oramed Pharmaceuticals (Israel) | Metabolic diseases |
| 2016-11-29 | aldoxorubicin | soft tissue sarcoma | 3 | CytRx Corporation (USA - CA) | Cancer - Oncology |
| 2016-11-28 | PM01183 (lurbinectidin) | solid tumors | 1 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-11-28 | Faslodex® (fulvestrant) | hormone receptor positive breast cancer | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2016-11-28 | GBT440 | idiopathic pulmonary fibrosis (IPF) | 2a | Global Blood Therapeutics (USA - CA) | |
| 2016-11-28 | eptinezumab - ALD403 | chronic migraine | 3 | Alder Biopharmaceuticals (USA - WA) | CNS diseases - Neurological diseases |
| 2016-11-24 | daprodustat | anemia associated with chronic kidney disease | 3 | GSK (UK) | Kidney diseases - Renal diseases |
| 2016-11-23 | JCAR015 - autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor) | acute lymphoblastic leukemia (ALL) | 2 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2016-11-22 | durvalumab (MEDI4736) and tremelimumab | squamous cell carcinoma of the head and neck | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2016-11-22 | TG-1101 (ublituximab) and TGR-1202 | chronic lymphocytic leukemia (CLL) | 3 | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2016-11-22 | filgotinib | Crohn's disease | 3 | Gilead Sciences (USA - CA) Galapagos (Belgium) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-11-22 | ABTL0812 (sodium 2-hydroxylinoleate) | endometrial or squamous lung cancer | 2 | Ability Pharmaceuticals (Spain) | Cancer - Oncology |
| 2016-11-22 | co.don chondrosphere® (ACT3D-CS) | cartilage defects of the knee | 2 | co.don (Germany) | Bone diseases - Regenerative medicine |
| 2016-11-21 | Multikine® (Leukocyte Interleukin, Injection) | head and neck cancer | 3 | CEL-SCI Corporation (USA -VA) | Cancer - Oncology |
| 2016-11-18 | biosimilar etanercept | moderate to severe chronic plaque-type psoriasis | 3 | Sandoz (Switzerland) | Autoimmune diseases – Dermatological diseases |
| 2016-11-18 | AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor | isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma | 1 | Agios Pharmaceuticals (USA -MA) | Cancer - Oncology |
| 2016-11-18 | GLPG2737 | cystic fibrosis | 1 | Gilead Sciences (USA - CA) | Rare diseases - Genetic diseases |
| 2016-11-17 | NEO-PV-01 and nivolumab | measurable metastatic melanoma, non-small cell lung cancer, bladder cancer. | 1b | Neon Therapeutics (USA - MA) | Cancer - Oncology |
| 2016-11-17 | Viaskin rPT® | reactivation of immunity against Bordetella pertussis (whooping cough) | 1 | DBV Technologies (France) Geneva University Hospitals (Switzerland) BioNet-Asia (Thailand) | Infectious diseases |
| 2016-11-17 | FR104 | rheumatoid arthritis, kidney transplantation | 1 | Effimune (France) now OSE Immunotherapeutics (France) Janssen Biotech, a J&J company (USA - NJ) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Transplantation |
